Related Experiment Video
Updated: Jul 20, 2026
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based
Howard W Salmon1, Christopher Mladinich, Dietmar W Siemann
1Department of Radiation Oncology, Shands Cancer Center at the University of Florida, Gainesville, FL, USA. hwsalmon@cox.net <hwsalmon@cox.net>
Abstract:
The present study evaluated the treatment efficacy of the vascular disrupting agents CA4P and OXi4503 in an orthotopically transplanted human renal cell carcinoma xenograft model (Caki-1). Experiments used vascular casting, vessel density assessments as well as tumour necrosis measurements to evaluate the efficacy of these agents. After treatment with either agent, assessment of the vascular casts showed an almost total eradication of tumour blood vessels. Histological evidence further supported this observation, showing extensive central tumour necrosis with only a small viable rim of tumour cells remaining at the periphery. These results suggest that vascular disrupting agents CA4P and OXi4503 may have utility in the treatment of renal cell carcinoma, an encouraging result given that current conventional therapies have been currently largely unsuccessful in managing this disease.
Insights
Vascular disrupting agents CA4P and OXi4503 effectively eradicated tumor blood vessels and induced necrosis in renal cell carcinoma models. This offers a promising new therapeutic avenue for this challenging cancer.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) presents a significant therapeutic challenge, with limited success of conventional treatments.
- Vascular disrupting agents (VDAs) offer a novel approach by targeting tumor vasculature.
Purpose of the Study:
- To evaluate the efficacy of two VDAs, CA4P and OXi4503, in a human RCC xenograft model.
- To assess the impact of these agents on tumor vascularization and cell viability.
Main Methods:
- Orthotopic xenograft model using human Caki-1 renal cell carcinoma cells.
- Vascular casting, vessel density assessment, and tumor necrosis measurements.
- Histological analysis of tumor tissue post-treatment.
Main Results:
- CA4P and OXi4503 treatments led to near-complete eradication of tumor blood vessels.
- Extensive central tumor necrosis was observed, with minimal viable tumor cells at the periphery.
- Vascular casting revealed significant disruption of the tumor vascular network.
Conclusions:
- VDAs CA4P and OXi4503 demonstrate potent anti-tumor activity in an RCC model.
- These agents show potential as a novel therapeutic strategy for renal cell carcinoma.
- The findings encourage further investigation into VDAs for managing RCC.
